Trial Profile
A Phase Ib Study of the Safety and Pharmacokinetics of Atezolizumab (Anti-PD-L1 Antibody) Alone or in Combination With an Immunomodulatory Drug and/or Daratumumab in Patients With Multiple Myeloma (Relapsed/Refractory and Post-Autologous Stem Cell Transplantation)
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Atezolizumab (Primary) ; Daratumumab (Primary) ; Lenalidomide (Primary) ; Pomalidomide (Primary) ; Dexamethasone
- Indications Multiple myeloma
- Focus Adverse reactions; Therapeutic Use
- Sponsors Genentech; Roche
- 31 Mar 2021 Status changed from active, no longer recruiting to completed.
- 28 Apr 2020 Planned End Date changed from 26 Sep 2020 to 29 Oct 2021.
- 28 Apr 2020 Planned primary completion date changed from 26 Sep 2020 to 29 Oct 2021.